| Roche product predicted to accumulate fifth of breast cancer drug market in 2017 | Posted on 22/10/2008 in Scientific Roche is expected to accumulate more than a fifth of total breast cancer drug sales in the UK, US, Japan, France, Italy, Germany and Spain in 2017 with one of its products, according to a report.
Sales of Genentech/Roche/Chugai's Avastin in the US and Europe and its launch in Japan will drive the cancer drug market, the new Pharmacor report from Decision Resources - entitled Breast Cancer - found.
Furthermore, Herceptin – from the same company – continues to head the market segment for human epidermal growth factor receptor-2 (HER2) positive breast cancer, the report said.
Dr Niamh Murphy, analyst at Decision Resources, said: "There is a significant unmet need for the development of effective agents for the treatment of triple-negative breast cancer."
This is due to the "lack of receptor expression results in resistance to conventional hormonal and targeted therapies" which leaves chemotherapy as the only choice for triple-negative breast cancer patients, she explained.
People looking for scientific sales jobs may be interested Roche's other products, which include MabThera and Viracept.
 Other news stories from 22/10/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
